Neuroblastoma in children aged ≥1 to ≤21 years research hub

A trial of BEvACizumab added to temozolomide +/- irinOtecan for children with refractory/relapsed Neuroblastoma

This study looks at new treatment combinations for children and young people with neuroblastoma that has returned or stopped responding to standard therapy. Researchers want to see if adding an antibody drug called bevacizumab to chemotherapy can help control the cancer and improve treatment options.